Skip to main content
Premium Trial:

Request an Annual Quote

Accler8 s Losses Widen in Q1; BACcelr8r Promised in 2006

NEW YORK, Dec. 16 (GenomeWeb News) - Accelr8 Technology today said that despite quadrupling its total revenue for the first fiscal quarter for 2006, net losses widened.

 

The company said total revenues for the three months ended Oct. 31 increased to $86,388 from $21,724 in the year-ago period

 

Net loss for the quarter increased 51 percent to $772,000, or $.08 per share, from $509,800, or $.05 per share, year over year, the Denver-based company said.

 

The company reported research and development expenses of $573,000 for the quarter, a 182-percent increase over the $203,000 reported for the same quarter last year. The increase is attributed to the development of the BACcelr8r diagnostic system.

 

Accelr8 expects to complete studies on materials and processes for the system and begin selling it in fiscal 2006, the company said.

 

Acceler8 reported cash and cash equivalents of $4.9 million on hand as of Oct. 31.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.